Woolf, Clifford

The Journal of Headache and Pain

Harvard University - DASH 

 Analgesic drug development: time to break the mould  (Article begins on next page)The Harvard community has made this article openly available.Please share how this access benefits you. Your story matters.Citation Woolf, Clifford. 2013. “Analgesic drug development: time tobreak the mould.” The Journal of Headache and Pain 14 (Suppl1): I2. doi:10.1186/1129-2377-14-S1-I2.http://dx.doi.org/10.1186/1129-2377-14-S1-I2.Published Version doi:10.1186/1129-2377-14-S1-I2Accessed February 19, 2015 2:31:29 PM ESTCitable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:11877041Terms of Use This article was downloaded from Harvard University's DASHrepository, and is made available under the terms and conditionsapplicable to Other Posted Material, as set forth athttp://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAAINVITED SPEAKER PRESENTATION Open AccessAnalgesic drug development: time to breakthe mouldClifford WoolfFrom The European Headache and Migraine Trust International CongressLondon, UK. 20-23 September 2012Success in the introduction of novel, effective and safeanalgesics has been notably limited over the past ten yearseven though existing treatments have low responder ratesand a high side effect burden. The pipeline of compoundsacting on novel targets is very restricted and there havebeen many disappointments with drugs that appearedpromising in preclinical studies, failing repeatedly in clini-cal trials. We have to recognize that something is funda-mentally wrong with the industry standard approach tothe selection of targets, identification of hits, validation ofleads and proof of concept clinical studies. A radicallyalternative strategy is required, one that is driven by thepatient and focused on disease phenotype. I will discusswhat such an approach may look like and how it maycontribute to new therapeutics.Published: 21 February 2013doi:10.1186/1129-2377-14-S1-I2Cite this article as: Woolf: Analgesic drug development: time to breakthe mould. The Journal of Headache and Pain 2013 14(Suppl 1):I2.Submit your manuscript to a journal and beneﬁ  t from:7 Convenient online submission7 Rigorous peer review7 Immediate publication on acceptance7 Open access: articles freely available online7 High visibility within the ﬁ  eld7 Retaining the copyright to your article    Submit your next manuscript at 7 springeropen.comF.M. Kirby Neurobiology Center, Boston Children’s Hospital and Departmentof Neurobiology, Harvard Medical School, Boston MA, USAWoolf The Journal of Headache and Pain 2013, 14(Suppl 1):I2http://www.thejournalofheadacheandpain.com/content/14/S1/I2© 2013 Woolf; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons AttributionLicense (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,provided the original work is properly cited.

Analgesic drug development: time to break the mould

Clifford Woolf

Springer - Publisher Connector

INVITED SPEAKER PRESENTATION Open Access
Analgesic drug development: time to break
the mould
Clifford Woolf
From The European Headache and Migraine Trust International Congress
London, UK. 20-23 September 2012
Success in the introduction of novel, effective and safe
analgesics has been notably limited over the past ten years
even though existing treatments have low responder rates
and a high side effect burden. The pipeline of compounds
acting on novel targets is very restricted and there have
been many disappointments with drugs that appeared
promising in preclinical studies, failing repeatedly in clini-
cal trials. We have to recognize that something is funda-
mentally wrong with the industry standard approach to
the selection of targets, identification of hits, validation of
leads and proof of concept clinical studies. A radically
alternative strategy is required, one that is driven by the
patient and focused on disease phenotype. I will discuss
what such an approach may look like and how it may
contribute to new therapeutics.
Published: 21 February 2013
doi:10.1186/1129-2377-14-S1-I2
Cite this article as: Woolf: Analgesic drug development: time to break
the mould. The Journal of Headache and Pain 2013 14(Suppl 1):I2.
Submit your manuscript to a 
journal and benefi t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the fi eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
F.M. Kirby Neurobiology Center, Boston Children’s Hospital and Department
of Neurobiology, Harvard Medical School, Boston MA, USA
Woolf The Journal of Headache and Pain 2013, 14(Suppl 1):I2
http://www.thejournalofheadacheandpain.com/content/14/S1/I2
© 2013 Woolf; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium,
provided the original work is properly cited.


http://dash.harvard.edu/bitstream/handle/1/11877041/3619983.pdf?sequence=1

Analgesic drug development: time to break the mould

Abstract

Similar works

Full text

Available Versions

Harvard University - DASH

Springer - Publisher Connector